26974-77-6

Upstream product

• 590-92-1 3-Bromopropionic acid 
• 95-51-2 o-chloroaniline 
• 15486-96-1 3-Bromopropionyl chloride 

Downstream Products

• 100222-14-8 N-(2-Chloro-phenyl)-3-(1,3,4,6,11,11a-hexahydro-pyrazino[1,2-b]isoquinolin-2-yl)-propionamide 
• 1393644-11-5 N-hydroxy-4-{[(2-chlorophenylcarbamoylethyl)amino]methyl}benzamide 
• 21617-11-8 8-chloro-2,3-dihydro-1H-quinolin-4-one 
• 890841-86-8 C₉H₈ClNO 
• 100222-00-2 N-(2-Chloro-phenyl)-3-(3,4,6,7,12,12a-hexahydro-1H-pyrazino[1',2':1,6]pyrido[3,4-b]indol-2-yl)-propionamide 
• 100222-04-6 3-(4-Benzyl-piperazin-1-yl)-N-(2-chloro-phenyl)-propionamide 
• 100222-09-1 3-(4-Benzyl-piperidin-1-yl)-N-(2-chloro-phenyl)-propionamide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of hydroxamic acid derivatives as potential high density lipoprotein (HDL) receptor CLA-1 up-regulating agents

Trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) were reported in our recent publication as novel human high density lipoprotein (HDL) receptor CD36 and Lysosomal integral membrane protein-II Analogous-1 (CLA-1) up-regulators. As part of a

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Synthesis, biological evaluation, and quantitative structure. A new class of potent H1 antagonists

Some [β-(Aroylamino)ethyl]piperazines and -piperidines and [2-[(Arylamino)carbonyl]ethyl]piperazines, -piperidines, -pyrazinopyridoindoles, and -pyrazinoisoquinolines have been synthesized and their H1-antagonistic activity studied in isolated guinea pig